CHU Besançon   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Besançon France (1745)

Organization Overview

First Clinical Trial
1993
NCT00002523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Besançon University Hospital | Central Hospital, Besançon, France | Centre Hospitalier Jean Minjoz | Centre Hospitalier Universitaire de Besançon | CHRU Jean Minjoz, Besançon, France | CHU Besançon | CHU de Besançon | Hopital Jean Minjoz | HOPITAL JEAN MINJOZ - BESANCON CEDEX | Rheumatology department, CHU Besançon, France | University Hospital of Besançon | University Hospital Saint jacques, Besançon

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Anus Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Rectal Neoplasms (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Urticaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 21